TY - JOUR
T1 - Probiotics and gut health
AU - Scarpellini, Emidio
AU - Basilico, Martina
AU - Rinninella, Emanuele
AU - Carbone, Florencia
AU - Schol, Jolien
AU - Rasetti, Carlo
AU - Abenavoli, Ludovico
AU - Santori, Pierangelo
PY - 2021
Y1 - 2021
N2 - Gut microbiota is a complex ecosystem of bacteria, viruses, archea, protozoa and yeasts in our intestine. It has several functions which maintain human body equilibrium. Microbial "dysbiosis" can be responsible for several gastrointestinal diseases. To build a narrative review we performed a Pubmed, Medline, Embase search for English language papers, reviews, meta-analyses, case series, and randomized controlled trials (RCTs) by keywords and their associations. Gut microbiota is altered in several gastrointestinal diseases with very different pathophysiology. They range from multifactorial diseases such as irritable bowel syndrome (IBS), nonalcoholic fatty liver disease (NAFLD) and gastric and colorectal cancers, immune-mediated such as celiac disease, inflammatory bowel diseases (IBD), and antibiotic-related such as clostridium difficile infection (CDI). Microbial dysbiosis remodulation by probiotics is feasible and safe in some of them. Gut microbial dysbiosis is statistically associated with several gastrointestinal diseases, affecting their pathophysiology. Its reverse by probiotics has some promising evidence of efficacy.
AB - Gut microbiota is a complex ecosystem of bacteria, viruses, archea, protozoa and yeasts in our intestine. It has several functions which maintain human body equilibrium. Microbial "dysbiosis" can be responsible for several gastrointestinal diseases. To build a narrative review we performed a Pubmed, Medline, Embase search for English language papers, reviews, meta-analyses, case series, and randomized controlled trials (RCTs) by keywords and their associations. Gut microbiota is altered in several gastrointestinal diseases with very different pathophysiology. They range from multifactorial diseases such as irritable bowel syndrome (IBS), nonalcoholic fatty liver disease (NAFLD) and gastric and colorectal cancers, immune-mediated such as celiac disease, inflammatory bowel diseases (IBD), and antibiotic-related such as clostridium difficile infection (CDI). Microbial dysbiosis remodulation by probiotics is feasible and safe in some of them. Gut microbial dysbiosis is statistically associated with several gastrointestinal diseases, affecting their pathophysiology. Its reverse by probiotics has some promising evidence of efficacy.
KW - Clostridium Infections
KW - Dysbiosis
KW - Gastrointestinal Microbiome
KW - Gastrointestinal diseases
KW - Gastrointestinal microbiome
KW - Humans
KW - Irritable Bowel Syndrome
KW - Probiotics
KW - Clostridium Infections
KW - Dysbiosis
KW - Gastrointestinal Microbiome
KW - Gastrointestinal diseases
KW - Gastrointestinal microbiome
KW - Humans
KW - Irritable Bowel Syndrome
KW - Probiotics
UR - http://hdl.handle.net/10807/194564
U2 - 10.23736/S2724-5985.21.02910-7
DO - 10.23736/S2724-5985.21.02910-7
M3 - Article
SN - 2724-5985
VL - 67
SP - 314
EP - 325
JO - Minerva Gastroenterology
JF - Minerva Gastroenterology
ER -